The full Eli Lilly (LLY) reaction history

LLY news moved a median of +0.06% by the close. Every LLY news event with the realized, point-in-time move the market made — the same measurement, headline by headline. Back to the LLY overview →

Half of the 393 LLY news events with a measured close landed between -0.79% and +0.96%; 53% closed up.

By year and event type

LLY reaction counts across 4 years.

Event type2026202520242023Total
Press release1031169326338
SEC filing · Form 8-K5913128
SEC filing · Form 10-Q23319
SEC filing · Form 10-K11103
SEC filing · Form 11-K11103
SEC filing · Form DEF11103
SEC filing · Form DEFA14A11103
SEC filing · Form PRE11103
SEC filing · Form SD11103
SEC filing · Form S-3ASR01001
All types11613511528394

Counts from the full measured window for LLY, not just the free rows below — every event type we have labeled, year by year.

Archive pages

Older LLY news pages.

Page 1 is the LLY overview; pages 2–8 carry the rest of the measured list.

The 10 most recent LLY reactions.

DateHeadlineEventSource5-minTo close
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020Press releasePR Newswire-0.14%+0.08%
Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitisPress releasePR Newswire+0.72%-0.06%
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPress releasePR Newswire+0.72%-0.06%
Lilly confirms date and conference call for third-quarter 2026 financial results announcementPress releasePR Newswire+0.24%-0.45%
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one yearPress releasePR Newswire+0.37%+1.02%
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesityPress releasePR Newswire+1.10%+2.40%
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditionsPress releasePR Newswire+1.02%-0.66%
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLLPress releasePR Newswire+0.01%-0.39%
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular diseasePress releasePR Newswire-0.65%-0.31%
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetesPress releasePR Newswire+0.59%-2.88%

384 more LLY reactions are behind a free account. Create one to see all 394 measured LLY events — the same point-in-time reactions, every headline.

See all 394 LLY events →

No credit card · 100 free credits/mo

Keep exploring

More LLY: earnings → · analyst actions → · SEC filings → · LLY overview →

Other Health Care names, measured the same way

TickerEventsMedian 30-min% positive
Johnson & Johnson (JNJ)2,000++0.06%56%
UnitedHealth Group (UNH)2,000+-0.03%48%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.